Patent blue sentinel node mapping in cervical cancer patients may lead to decreased pulse oximeter readings and positive methaemoglobin results.

@article{Kieckbusch2008PatentBS,
  title={Patent blue sentinel node mapping in cervical cancer patients may lead to decreased pulse oximeter readings and positive methaemoglobin results.},
  author={H Kieckbusch and Sina M. Coldewey and Josef Hollenhorst and Gertrud Haeseler and Peter Hillemanns and Hermann Hertel},
  journal={European journal of anaesthesiology},
  year={2008},
  volume={25 5},
  pages={
          365-8
        }
}
BACKGROUND AND OBJECTIVE Patent blue (4-[(4-diethylaminophenyl)-(4-diethylazaniumylidencyclohexa-2,5-dienyliden) methyl]-6-hydroxy-3-sulfo-benzolsulfonate, sodium salt) is a contrast dye used for the intraoperative detection of the primary lymphatic nodes draining the area of tumour infiltration. The dye is known to interact with pulse oximeter readings. However, the degree of alteration seems to be moderate and predictable when patent blue is injected into the perimammilar region during breast… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 10 REFERENCES